Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | FABP6 | P51161 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23556669 | 1.00 | RECQL (0.51) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL23539643 | 1.00 | RECQL (0.51) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL25154275 | 0.82 | RECQL (0.52) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL6933242 | 0.80 | CA1 (0.54) | RECQLSMN1; SMN2 | |
| SCHEMBL25154276 | 0.76 | CA1 (0.48) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL25154742 | 0.76 | CA1 (0.48) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL30259445 | 0.74 | SIGMAR1 (0.48) | RECQLSMN1; SMN2ALDH1A1FABP6 | |
| SCHEMBL1029651 | 0.73 | RECQL (0.73) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A | |
| SCHEMBL5745900 | 0.72 | MAPT (0.51) | MEN1KMT2AALDH1A1NR1H2NR1H3 | |
| SCHEMBL25484823 | 0.71 | GBA1 (0.44) | RECQLSMN1; SMN2CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | RECQL 592/4885SMN1; SMN2 1154/4885CYP2D6 9/4885 |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | RECQL 861/4885SMN1; SMN2 1205/4885CYP2D6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.